跳转至内容
Merck
CN

384R-1

SATB2 (EP281) Rabbit Monoclonal Primary Antibody

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

rabbit

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP281, monoclonal

description

(For In Vitro Diagnostic Use in Select Regions (See Chart))

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (384R-14)
vial of 0.5 mL concentrate (384R-15)
bottle of 1.0 mL predilute (384R-17)
vial of 1.0 mL concentrate (384R-16)
bottle of 7.0 mL predilute (384R-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

isotype

IgG

control

colon adenocarcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Quality Level

Gene Information

human ... SATB2(23314)

Analysis Note


IVD

IVD

IVD

RUO

General description

Special AT-rich sequence-binding protein 2 (SATB2) is a marker that functions as a nuclear matrix-associated transcription factor that has been shown to identify colorectal carcinomas, including poorly differentiated colorectal carcinomas and metastases. Adenocarcinomasincluding breast, lung, and ovary may express SATB2 at lower frequencies.1 Therefore, SATB2 is useful for identifying a carcinoma of colorectal origin when identifying a cancer of unknown primary.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
SATB2 Positive Control Slides, Product No. 384S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Fan Lin et al.
Archives of pathology & laboratory medicine, 138(8), 1015-1026 (2014-01-21)
Distinction of medullary carcinoma of the large intestine from other cytokeratin (CK) 7⁻/CK20⁻ carcinomas can be challenging when working on a tumor of unknown primary because the majority of medullary carcinomas are negative for CK7, CK20, and CDX2. To investigate
Michelle Moh et al.
The American journal of surgical pathology, 40(3), 419-432 (2015-11-10)
The primary origin of some ovarian mucinous tumors may be challenging to determine, because some metastases of extraovarian origin may exhibit gross, microscopic, and immunohistochemical features that are shared by some primary ovarian mucinous tumors. Metastases of primary colorectal, appendiceal
Anca Dragomir et al.
American journal of clinical pathology, 141(5), 630-638 (2014-04-10)
Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type
Yi-Jun Zhang et al.
EBioMedicine, 28, 62-69 (2018-02-06)
SATB2 (Special AT-rich sequence-binding protein 2) has recently been shown to be a specific biomarker of colorectal cancer (CRC). The aim of this study was to investigate the diagnostic potential of SATB2 as a means of detecting a CRC origin
Stefan M Brettfeld et al.
Archives of pathology & laboratory medicine, 143(9), 1119-1125 (2019-03-07)
Metastatic mucinous tumors present a diagnostic challenge for pathologists as tumor histomorphology is often nonspecific and optimal immunoprofiles are still under investigation. To present a head-to-head comparison of special AT-rich sequence-binding protein 2 (SATB2) and caudal type homeobox 2 (CDX2)

商品

Colorectal cancer is the third most common cancer in both men and women. An estimated 136,000 cases of colorectal cancer are expected to occur in 2016.

结直肠癌是男性和女性中第三大常见癌症。预计2016年将发生136,000例结直肠癌。

相关内容

诊断性免疫组化是一系列用于识别组织异常、建立预后并提示治疗方式的技术。其基本原理是一种抗原-抗体结合反应,利用酶或荧光染料来标记抗体,呈现出组织或组织切片中特定抗原的位置和分布。

Diagnostic immunohistochemistry overview highlights its importance in cancer diagnosis and detecting infectious diseases in modern clinical pathology.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持